BioNTech (BNTX) vs Krystal Biotech (KRYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Krystal Biotech (KRYS) has outperformed BioNTech (BNTX) over the past year, gaining 45.7% versus a loss of 15.3%. Over five years, KRYS leads with a +675.9% price change compared with -76.7% for BNTX. BioNTech is the larger company by market cap ($20.07 billion vs $9.15 billion), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | KRYS |
|---|---|---|
| Share price | $80.96 | $308.89 |
| Market cap | $20.07B | $9.15B |
| 1-day change | -0.52% | -2.19% |
| YTD return | -14.96% | +25.29% |
| 1-year return | -15.30% | +45.69% |
| 5-year return | -76.74% | +675.91% |
| P/E ratio (TTM) | — | 41.97 |
| Forward P/E | — | 33.47 |
| EPS (TTM) | $-6.83 | $7.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $389.13M |
| Revenue growth (YoY) | — | +33.94% |
| Net income (latest FY) | — | $204.83M |
| Operating margin | — | 41.45% |
| Net margin | — | 52.64% |
| 52-week high | $124.00 | $382.54 |
| 52-week low | $79.52 | $212.02 |
| Distance from 52-week high | -34.71% | -19.25% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.51% | +25.68% |
| Average volume | 1.08M | 283.88K |
| Shares outstanding | 247.93M | 29.63M |
| Employees | 7,807 | 295 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioNTech is about 2.2 times larger than Krystal Biotech by market value ($20.07B vs $9.15B).
- KRYS has outperformed BNTX by 61.0 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Krystal Biotech
KRYS stock →Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 295 employees
BNTX vs KRYS FAQ
Which is bigger, BioNTech or Krystal Biotech?
BioNTech (BNTX) is larger, with a market capitalization of $20.07B compared with $9.15B for Krystal Biotech (KRYS).
Which stock has performed better over the past year, BNTX or KRYS?
KRYS returned +45.69% over the past 12 months, compared with -15.30% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Krystal Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.